for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharma Mar SA

PHMR.MC

Latest Trade

1.80EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.00

 - 

2.42

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
1.80
Open
--
Volume
--
3M AVG Volume
17.01
Today's High
--
Today's Low
--
52 Week High
2.42
52 Week Low
1.00
Shares Out (MIL)
221.28
Market Cap (MIL)
402.33
Forward P/E
-13.39
Dividend (Yield %)
--

Latest Developments

More

Pharma Mar 9-Month Net Loss Widens To 27 Mln Euros YoY

Pharma Mar Signs New Deal With STA To Commercialize Yondelis In Australia, New Zealand And Southeast Asia

Pharma Mar And Janssen Enter Into New Licensing Agreement For Yondelis In US

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pharma Mar SA

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.

Industry

Biotechnology & Drugs

Contact Info

Avda. De los Reyes, 1, Pol. Ind. La Mina

+34.918.466000

https://www.pharmamar.com/es/

Executive Leadership

Jose Maria Fernandez Sousa-Faro

President, Chief Executive Officer, Executive Chairman of the Board

Pedro Fernandez Puentes

Executive Vice Chairman

Maria Luisa de Francia Caballero

Chief Financial Officer

Luis Ruperez Cuenca

Director of Human Resources and IT

Nadia Badri

Vice President - Medical Affairs

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.1K
EPS (EUR)

2016

-0.110

2017

-0.120

2018

-0.300

2019(E)

-0.135
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.39
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-45.24
Return on Equity (TTM)
-24.55

Latest News

Latest News

BRIEF-Pharma Mar Says Lurbinectedin Achieves Positive Results In Phase II Trial For Treatment Of Small Cell Lung Cancer

* SAID ON SATURDAY LURBINECTEDIN ACHIEVED PRIMARY ENDPOINT OF OVERALL RESPONSE RATE (ORR) IN PHASE II TRIAL

BRIEF-Pharma Mar To Sell Its Stake in Zelnova Zeltia

* SAID ON MONDAY IT HAD GRANTED A MANDATE TO ALANTRA CORPORATE FINANCE SAU FOR THE SALE OF ITS STAKE IN ITS UNIT ZELNOVA ZELTIA SA

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon:

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue

* PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE) Source text for Eikon:

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment

* SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY

BRIEF-Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre

* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA

BRIEF-Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY

* 9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO

BRIEF-Pharma Mar presents updated data from Zepsyre Phase I/II trials in SCLC

* PROGRESSION FREE SURVIVAL BENEFIT OBSERVED IN COMBINATION OF PM1183 AND DOXORUBICIN IN SMALL-CELL LUNG CANCER (SCLC)

BRIEF-Pharma Mar submits MAA for Aplidin in Switzerland for multiple myeloma treatment

* SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) FOR APLIDIN IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA Source text: http://bit.ly/2xf24h3

BRIEF-Pharma Mar starts clinical studies with new compound PM14 in patients with solid tumors

* SAYS STARTS CLINICAL STUDIES WITH NEW COMPOUND PM14 IN PATIENTS WITH SOLID TUMORS Source text for Eikon:

BRIEF-Pharma Mar presents response rate data with PM1183 in patients with lung cancer

* NEW POSITIVE DATA ON PM1183 SEES RESPONSE RATE OF 36 PERCENT AS SINGLE AGENT IN PATIENTS WITH ADVANCED AND RELAPSED SMALL-CELL LUNG CANCER

BRIEF-Pharma Mar unit presents positive results for lung cancer diagnostic kit

* ITS UNIT GENOMICA PRESENTS POSITIVE RESULTS FOR ITS CLART CMA EGFR DIAGNOSTIC KIT FOR NON-SMALL CELL LUNG CANCER (NSCLC) FOR HOSPITAL USE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up